TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27759458
Drug: Amberen dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amberen dietary supplement
Study: 15964160
Drug: CEE/MPA 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA 5 mg
Study: 15964160
Drug: CEE/MPA 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA 2.5 mg
Study: 10687548
Drug: Static surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static surface (gel pad)
Study: 8681149
Drug: 5-cc saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-cc saline bolus
Study: 2028354
Drug: Analgesic/anti-inflammatory combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic/anti-inflammatory combined medication (Myprodol; Rio Ethicals)
Study: 2028354
Drug: Anti-inflammatory medication
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory medication (Voltaren; Geigy)
Study: 16154735
Drug: Regular intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intermittent epidural boluses (5 mL every half hour)
Study: 16154735
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of levobupivacaine 0.1% with fentanyl 2 microg/mL at a rate of 10 mL/h
Study: 10421644
Drug: Somatostatin (SMT)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SMT) infusion (250 micrograms/h) for 5 days
Study: 10421644
Drug: Somatostatin (SMT)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SMT) infusion (250 micrograms/h) for 5 days + sclerotherapy
Study: 27059729
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg twice daily for 12 weeks
Study: 25538468
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel after scaling and root planing (SRP)
Study: 8450326
Drug: Nicardipine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (0.15 mg/kg/hr by continuous infusion for up to 14 days)
Study: 3828486
Drug: pH 2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH 2.3 solution of 0.5 mg triazolam
Study: 3828486
Drug: pH 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH 6.0 solution of 0.5 mg triazolam
Study: 3828486
Drug: pH 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH 6.0 solution of 0.5 mg triazolam during cimetidine treatment (1200 mg day-1)
Study: 30957525
Drug: Cognitive‐Behavioral Therapy‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioral Therapy‐based integrated treatment/management program (active treatment condition)
Study: 27126198
Drug: 54 mg
Normalized name: aspirin 454 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 mg genistein daily for 1 year
Study: 25519790
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of antiretroviral therapy (ART) within 2 weeks
Study: 25519790
Drug: Deferred initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Deferred initiation of antiretroviral therapy (ART) starting a median of 1.3 years after enrollment
Study: 12632024
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (280 mg)
Study: 10692268
Drug: Amlodipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (mean dose, 9 mg/d)
Study: 10692268
Drug: Enalapril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (mean dose, 17 mg/d)
Study: 8225688
Drug: Nocloprost (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocloprost (200 micrograms) given twice daily for 8 days
Study: 31248676
Drug: Epinephrine dosing
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine dosing interval less than 3 minutes
Study: 31248676
Drug: Epinephrine dosing
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine dosing interval 3 to less than 4 minutes
Study: 31248676
Drug: Epinephrine dosing
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine dosing interval 4 to less than 5 minutes
Study: 31248676
Drug: Epinephrine dosing
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine dosing interval greater than or equal to 5 minutes
Study: 25425373
Drug: Sequential arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential arm - 3 transabdominal cervical length measurements obtained, transvaginal sonography performed if images were inadequate or if any measurement was 3 cm or less
Study: 8151462
Drug: Ceftriaxone, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, 50 mg/kg intramuscularly
Study: 8151462
Drug: Amoxicillin, 20
Normalized name: Amoxicillin, 200 mg oral tablet, chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, 20 mg/kg/dose orally for six doses
Study: 21935965
Drug: Modified-release zaleplon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release zaleplon 15 mg (SKP-1041A, SKP-1041B, SKP-1041C)
Study: 21935965
Drug: Modified-release zaleplon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release zaleplon 15 mg (SKP-1041A, SKP-1041B)
Study: 21935965
Drug: Immediate-release zaleplon
Normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release zaleplon 10 mg
Study: 21935965
Drug: Modified-release zaleplon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release zaleplon 15 mg (SKP-1041)
Study: 11529537
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (GH) at a dose of 0.15 IU kg(-1) per day for 3 years (Group A: discontinuous, Group B: control for 1 year then continuous, Group C: continuous)
Study: 11529537
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (GH) (Group A: discontinuous, Group B: continuous after 1 year, Group C: continuous)
Study: 11529537
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (GH) (Group A: discontinuous, Group B: continuous, Group C: continuous)
Study: 11529537
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (GH) (Group A: discontinuous)
Study: 9555791
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid-based lipid emulsion (Omegavenous; 200 ml/day with 4.2 gm of both EPA and DHA)
Study: 9555791
Drug: Conventional omega-6-lipid
Normalized name: Omega 6 acids
DrugBank: Omega-6 fatty acids (DB13168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional omega-6-lipid emulsion (Lipovenous; EPA+DHA < 0.1 gm/100 ml)
Study: 2337211
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 ml saline with 0.5% bupivacaine)
Study: 204183
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: diet treatment from a clinic nutritionist with cooperation of the subject's private physician
Study: 204183
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: referral for treatment by a private physician
Study: 23596811
Drug: Nimodipine (drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (drug group)
Study: 21550374
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine (PPV), Haemophilus influenzae type b conjugate vaccine, and tetanus toxoid
Study: 21550374
Drug: PPV at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV at 7 or 17 weeks and second dose at 3 years of age
Study: 11768322
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day alpha-tocopherol for 14 days
Study: 11768322
Drug: 4g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g of ascorbic acid administered intravenously prior to induction
Study: 11768322
Drug: 4g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g of ascorbic acid administered in the cardioplegic solution
Study: 3148470
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg i.m.
Study: 3148470
Drug: Ketorolac 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 90 mg i.m.
Study: 29301824
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 (20 μg/day for 13 weeks, then 60 μg/day for 26 weeks)
Study: 22638548
Drug: HbA1c ≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbA1c ≤ 6.4% (≤ 46 mmol/l)
Study: 10684784
Drug: Carbamazepine 600-800
Normalized name: carbamazepine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 600-800 mg
Study: 1290731
Drug: Continuing medical
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing medical treatment
Study: 29782035
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet of rosuvastatin-ezetimibe
Study: 29782035
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of rosuvastatin and ezetimibe
Study: 27161611
Drug: Tocilizumab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (single dose prior to coronary angiography)
Study: 23106871
Drug: TL-pulsed DC-CIK
Normalized name: TL-895
DrugBank: TL-895 (DB16471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TL-pulsed DC-CIK cells immunotherapy
Study: 23106871
Drug: Interferon (IFN)-α
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN)-α immunotherapy
Study: 18818130
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no postoperative adjuvant therapy)
Study: 9744142
Drug: Budesonide Turbohaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Turbohaler 400 micrograms once daily
Study: 9744142
Drug: Budesonide Turbohaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Turbohaler 200 micrograms twice daily
Study: 7848948
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg intramuscularly before and after surgery
Study: 3139698
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist and HMG
Study: 30297663
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day n-3 LCPUFA as HiDHA™ tuna oil
Study: 30297663
Drug: 0.35 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.35 g/day n-3 LCPUFA as HiDHA™ tuna oil
Study: 30297663
Drug: 0.7 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g/day n-3 LCPUFA as HiDHA™ tuna oil
Study: 30297663
Drug: 0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/day n-3 LCPUFA (placebo - Sunola oil)
Study: 26507926
Drug: Topical eflornithine
Normalized name: eflornithine Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eflornithine applied twice daily for 6 months
Study: 26507926
Drug: No eflornithine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No eflornithine treatment (control)
Study: 20842042
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) with transdermal contraceptive patch (ethinyl estradiol and norelgestromin)
Study: 20842042
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) with oral contraceptive pill (ethinyl estradiol and norethindrone)
Study: 20842042
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) with transdermal contraceptive patch
Study: 18375093
Drug: rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.6 mg/kg + ephedrine 70 microg/kg (Group II)
Study: 18375093
Drug: rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.6 mg/kg + 0.9% saline (Group IV)
Study: 14670701
Drug: Compound stimuli
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound stimuli with element heterogeneity
Study: 14670701
Drug: Compound stimuli
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound stimuli with element homogeneity
Study: 1730278
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy MOCCA (vincristine, cyclophosphamide, lomustine, melphalan, methylprednisolone)
Study: 1730278
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy MOCCA
Study: 30328654
Drug: CRT-D (Cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D (Cardiac Resynchronization Therapy with a defibrillator)
Study: 29802791
Drug: Everolimus +
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus + reduced-dose calcineurin-inhibitor
Study: 22052627
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus low-level laser therapy (4 J/cm(2) at each point over a maximum of ten painful points for total 5 min duration)
Study: 22052627
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus low-level laser therapy
Study: 19864958
Drug: Perindopril and
Normalized name: perindopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril and Indapamide (active treatment)
Study: 12792664
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs (850-882 mg EPA and DHA as concentrated ethylesters)
Study: 12792664
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (1 g)
Study: 1611115
Drug: Intron A
Normalized name: Intron A
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intron A at 10 MU and mitomycin C (MMC) at 20 mg/instillation
Study: 1611115
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) at 20 mg/instillation
Study: 6377568
Drug: High-dose streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose streptokinase (100,000 U/h)
Study: 6377568
Drug: Low-dose streptokinase
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose streptokinase (approx 10,000 U/h) with low-dose heparin
Study: 30409926
Drug: Amorolfine 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine 0.25% cream
Study: 25090010
Drug: 2-hour psycho-education
Normalized name: MANGANESE DICATION
DrugBank: Manganese cation (DB06757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour psycho-education session combined with bi-weekly telephone support
Study: 21419391
Drug: FRIENDS cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRIENDS cognitive‐behavioral therapy (CBT) intervention
Study: 16849680
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori treatment (amoxicillin and omeprazole for 2 weeks)
Study: 16849680
Drug: Garlic supplement
Normalized name: Garlic 300 MG Oral Capsule [GARLIC SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic supplement (aged garlic extract and steam-distilled garlic oil for 7.3 years)
Study: 16849680
Drug: Vitamin supplement
Normalized name: Vitamin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplement (vitamin C, vitamin E, and selenium for 7.3 years)
Study: 11162751
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride (1200 mg/day, q.i.d. regimen)
Study: 11162751
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride (800 mg/day, b.i.d. regimen)
Study: 11162751
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride (600 mg/day)
Study: 11162751
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride (1200 mg/day)
Study: 1546820
Drug: Ketotifen, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen, 2 mg
Study: 1546820
Drug: Clemastine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine, 1 mg
Study: 1546820
Drug: Sodium cromoglycate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate, 10 mg
Study: 3935589
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment by phenoxymethyl penicillin
Study: 23274578
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg clopidogrel
Study: 22921739
Drug: Half-dose Pneumococcal
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose Pneumococcal vaccination with exercise
Study: 22921739
Drug: Full-dose Pneumococcal
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose Pneumococcal vaccination with exercise
Study: 10214169
Drug: Multisensory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisensory therapy
Study: 2121551
Drug: Protocol 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 2: daily GnRH‐a beginning in the midluteal phase, followed by 150 IU hMG after down regulation
Study: 2121551
Drug: Protocol 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 1: 100 mg of clomiphene citrate on days 5 to 9, followed by 150 IU hMG beginning on day 9
Study: 649030
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg domperidon t.i.d. for 4 weeks
Study: 29273079
Drug: Early Structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Structured Physiotherapy with an intra-articular steroid injection
Study: 29273079
Drug: Manipulation under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manipulation under anaesthesia with a steroid injection
Study: 27084728
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 1.25 μg once daily
Study: 27084728
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 2.5 μg once daily
Study: 21948942
Drug: Subcutaneous adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous adalimumab 80 mg at baseline followed by 40 mg every other week for 1 year
Study: 21948942
Drug: Intravenous infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infliximab 5 mg/kg
Study: 21948942
Drug: Subcutaneous adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous adalimumab
Study: 16113029
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine combined with chemotherapy
Study: 11932879
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CSA and MTX)
Study: 9474925
Drug: IL-3 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-3 at a dose of 5 micrograms/kg/day for 7 to 14 days
Study: 9474925
Drug: IL-11 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-11 at a dose of 50 micrograms/kg/day for 14 days
Study: 7535834
Drug: Single aural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single aural toilet and instillation of medicated ointment
Study: 2709485
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral polio vaccine (TOPV), 5 doses at intervals of 4 weeks
Study: 2709485
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral polio vaccine (TOPV), 2 doses
Study: 2709485
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral polio vaccine (TOPV), 3 doses
Study: 779704
Drug: Thioridazine hydrochloride
Normalized name: Thioridazine Hydrochloride
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine hydrochloride (15% to 50% of pretrial dose) combined with metyrosine
Study: 31349690
Drug: Polygonatum sibiricum
Normalized name: POLYGONATUM SIBIRICUM ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polygonatum sibiricum (PS) rhizome extract (500 mg/day, n = 40)
Study: 28848126
Drug: Other chemotherapy
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other chemotherapy group in the taxane group
Study: 19506839
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg pramipexole
Study: 19506839
Drug: 0.1875 mg
Normalized name: digoxin 0.1875 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1875 mg pramipexole